placeholder image

DR Andrew Kompa


  • Cardiovascular (Hypertrophy, cardiac function)
  • Clinical Pharmacology and Therapeutics (Signalling pathways, drug dicovery)
  • Nephrology (Fibrosis, renal function)



  • Dr Andrew Kompa has a background in cardiovascular pharmacology obtaining a PhD from the University of Melbourne in 1996. He continued his research in laboratory of Prof Roger Summers where he led studies investigating beta-adrenergic receptor and relaxin signalling pathways in cardiovascular disease. In 2002 Dr Kompa joined Prof Henry Krum’s laboratory at Monash University (Alfred Hospital) and took charge of the in vivo drug discovery lab within the Monash Centre of Cardiovascular Research and Education in Therapeutics. In the last decade, in collaboration with Prof Darren Kelly, Dr Kompa has directed his research efforts towards investigating the pathways implicated in models of cardiac and renal disease and cardiorenal syndrome. Using these models together with novel target inhibitors he has led multiple pre-clinical investigations examining the efficacy of these compounds. His current research interests focus on the role of uremic toxins in the renal and cardiorenal disease and the effects of these toxins on fibrotic, inflammatory and oxidative stress pathways.   


Member of

  • International Society for Heart Research - Australasia Section. Member and Presenter 1997 -
  • Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists. Member and Presenter 1990 -
  • American Heart Association. Member and Presenter 2012


Selected publications



Education and training

  • Grad Dip (Drug Eval Pharm Sci), University of Melbourne 1998
  • PhD, University of Melbourne 1996
  • BSc(Hons), University of Melbourne 1991



Available for supervision

  • Y